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Abstract
Since the turn of the century, a remarkable expansion has been achieved in the range and
effectiveness of products and strategies available to prevent, treat, and control malaria,
including advances in diagnostics, drugs, vaccines, and vector control. These advances
have once again put malaria elimination on the agenda. However, it is clear that even with
the means available today, malaria control and elimination pose a formidable challenge in
many settings. Thus, currently available resources must be used more effectively, and new
products and approaches likely to achieve these goals must be developed. This paper con-
siders tools (both those available and others that may be required) to achieve and maintain
malaria elimination. New diagnostics are needed to direct treatment and detect transmission
potential; new drugs and vaccines to overcome existing resistance and protect against clini-
cal and severe disease, as well as block transmission and prevent relapses; and new vector
control measures to overcome insecticide resistance and more powerfully interrupt trans-
mission. It is also essential that strategies for combining new and existing approaches are
developed for different settings to maximise their longevity and effectiveness in areas with
continuing transmission and receptivity. For areas where local elimination has been recently
achieved, understanding which measures are needed to maintain elimination is necessary
to prevent rebound and the reestablishment of transmission. This becomes increasingly
important as more countries move towards elimination.
Summary points
• Achieving malaria elimination likely requires new interventions and strategies in some
settings. In addition, the effectiveness of existing tools must be preserved and tools
deployed to counter the numerous challenges, key among which are the emergence and
spread of drug-resistant parasites and mosquitoes with resistance to vector control
measures.
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• The key research goal for diagnostics is the detection of populations with subclinical
infections and low parasite counts. Such diagnostics enable the development of effective
surveillance systems directed at malaria parasite elimination.
• The availability of new transmission-blocking drugs, vaccines, and vector control prod-
ucts would accelerate elimination where there is refractoriness to currently available
interventions. New regulatory pathways and product development models are needed
to efficiently develop and assess these new interventions.
• In areas endemic for Plasmodium vivax and P. ovale, the hypnozoite reservoir must be
targeted with more robust tools and strategies.
• In areas of declining transmission, as cases become less frequent, the contribution to
transmission of the subclinical parasite reservoir needs to be quantified and addressed
with transmission-blocking interventions.
• For vector control, addressing continuing escalation of insecticide resistance—including
through the identification of new chemical classes and longer-lasting insecticide formu-
lations—remains a priority. Changes in vector populations and behaviours must also be
addressed to restore responsiveness to existing interventions. In some areas, new para-
digms may be needed to understand how to design interventions that reduce vector
populations and receptivity to sufficiently low levels.
• Policy and decision makers, faced with chronic resource limitations, insufficient surveil-
lance, spatial and temporal heterogeneity of malaria parasite transmission, and multiple
intervention choices, need improved strategies and guidance on how, where, and when
to best combine and deploy existing and new interventions to maximise their longevity
and effectiveness.
Introduction
Achieving malaria parasite elimination across all countries (i.e., malaria eradication), especially
for those with a high disease burden, likely requires new tools and strategies to complement
existing interventions [1,2]. Given the inevitable uncertainties in product development and
given that different sets of tools will be applicable in different settings, a broad and imaginative
research and development agenda needs to be pursued. The research and development agenda
presented in this paper is in support of the WHO Global Technical Strategy for malaria goals
from 2016 to 2030, and tracking the progress of this research and development (R&D) agenda
and reevaluating the research needs will be required over time [2]. In Malaria Eradication
Research Agenda (malERA) 2011, diagnostics, drugs, vaccines, and vector control were con-
sidered separately [3–6]. However, for malERA Refresh, this paper considers together the
research agenda for all existing and prospective tools to accelerate progress towards achieving
and maintaining malaria elimination. In this case, the relationships between the different
research agendas can be more easily recognised. Other papers in this malERA Refresh series
consider the related discussions regarding the implementation and combination of tools [7],
implications of insecticide and antimalarial drug resistance [8], health system and policy issues
[9], and advances in basic science [10].
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Progress on tools for malaria elimination
Based on literature reviews and panel consultations [11], the most significant advances in the
development and deployment of malaria control and elimination tools between 2011 and 2015
were identified (S1–S4 Texts). For diagnostics, advances include widespread incorporation of
P. falciparum rapid diagnostic tests (RDTs) into routine malaria case management [12], devel-
opment of highly sensitive tools for detecting subclinical infections, and development and
deployment of combined tests that differentiate P. falciparum from P. vivax [13,14]. For drugs,
advances include the deployment of hundreds of millions of artemisinin-based combination
therapy (ACT) courses [12], publication of guidelines for mass drug administration (MDA)
[15], the recommendation of low-dose primaquine for transmission interruption [16], pro-
gression of new antimalarial compound classes into clinical development [17–19], field trials
to evaluate the potential role of medicines in killing mosquitoes (endectocides) [2], and the
identification of Kelch13 as a marker for artemisinin resistance, enabling mapping of its geo-
graphic distribution [20,21]. For vaccines, advances include the Article 58 positive opinion by
the European Medicines Agency and recommendations by the World Health Organization
(WHO) on the first vaccine targeting malaria, RTS,S-AS01E (Box 1) [22–33]; revision of the
Malaria Vaccine Technology Roadmap [34]; and new vaccines that progressed to clinical trials
[35,36]. For vector control, advances include registration of 2 additional long-lasting insecti-
cide formulations for indoor residual spraying (IRS) [37,38], field trials of dual-insecticide bed
nets [39–41], development programmes for new insecticides [42–44], and publication of the
larval source management operational manual by WHO [45]. Advances have also been made
in the ‘tools for developing tools’—for example, controlled human malaria infection (CHMI)
blood-stage parasite inoculation (Box 2) [46–56]; the human blood-stage challenge model for
early-stage determination of antimalarial drug pharmacokinetics/pharmacodynamics [57];
the development of human liver chimeric mice, human erythroid chimeric mice, and dually
engrafted mice allowing replication of the entire P. falciparum life cycle [58]; and validation of
phenotypic assays for gametocyte screening to identify compounds with transmission-block-
ing activity [59]. In addition, new technologies and scientific insights are emerging [10], with
notable improvements in mapping and modelling [7,60–62].
Diagnostics research agenda
Diagnostics for malaria treatment and elimination
To direct malaria treatment, all cases should be confirmed with a diagnostic test, either RDT
or light microscopy, even in low-transmission settings [63]. Current WHO criteria for RDT
procurement recommend a false positive rate of<10% [14]. However, a test with 99% specific-
ity, when used at the elimination threshold (prevalence of parasitaemia in the community of
0.1%), results in90% of positive tests coming from samples with no Plasmodium parasites
[64]. In very low-transmission settings, addressing the challenge of false positive tests may
require developing algorithms such as parallel or serial confirmation with a second test.
Recently, false-negative results for P. falciparum histidine-rich protein 2 (PfHRP2)-based
RDTs have been reported from several regions, caused by pfhrp2/pfhrp3 gene deletions [65–
70]. Universal validity of these diagnostic tests cannot be assumed, and the WHO has issued
guidance on PfHRP2-based RDT procurement [71].
Beyond P. falciparum, improved RDTs are needed for other species. Available lactate dehy-
drogenase (LDH)-targeting RDTs are less sensitive for P. vivax compared to P. falciparum,
because P. vivax parasite densities tend to be much lower [72]. There is a paucity of informa-
tion on test performance against minor species.
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Box 1. Malaria vaccine RTS,S/A101E
In 2015, the preerythrocytic candidate vaccine RTS,S/AS01E (RTS,S) received a positive
scientific opinion by European regulators through the Article 58 procedure. This was a
breakthrough in malaria vaccine development, identifying a regulatory pathway and
demonstrating that the large clinical trials necessary for approval could be conducted in
Africa [23–25].
• The target for RTS,S is the reduction of malaria incidence and severe disease in young
children. A 3-dose regimen was shown to reduce the number of malaria cases by half
in children 5–17 months of age during the first year following vaccination; efficacy
waned over time but was prolonged by a fourth dose [25].
• Despite modest efficacy, RTS,S prevented about 1,700 cases for every 1,000 children
vaccinated in a phase III study over a 4-year period, and modelling studies predict a
considerable public health impact for RTS,S, with the greatest benefit expected in areas
with the highest malaria burden [27].
• Following review of RTS,S data by the Strategic Advisory Group of Experts on Immu-
nization and the Malaria Policy Advisory Committee, in 2016 the WHO adopted rec-
ommendations for RTS,S pilot implementations in 3–5 settings involving 100,000–
200,000 children per setting (for a total of 400,000–800,000), in a staged manner to fur-
ther evaluate safety (including meningitis [26]), feasibility of delivery, and impact on
mortality.
• Phase IV studies with a primary objective of further evaluation of safety as part of the
Risk Management Plan approved by European Medicines Agency are planned to be
linked to the larger pilots, with complementary design and objectives [28,29].
Research to optimize the regimen and explore additional applications of RTS,S
. Optimising the RTS,S dosing regimen
Additional controlled human malaria infection (CHMI) and phase IIb studies are in
progress to better define how to improve RTS,S/AS01 efficacy and how these data trans-
late to the field, respectively.
• A small study with RTS,S and an earlier adjuvant (AS02) found that fractional dos-
ing, i.e., 2 full monthly doses plus a third low-dose at 7 months, resulted in apparent
high efficacy against P. falciparum challenge (6/7 protected) [30].
• A recent CHMI study in a larger number of volunteers using RTS,S/AS01 confirmed
that a 0-, 1-, 7-month regimen that included a fractional third dose (Fx017M) was
associated with higher efficacy (86.7% [95% confidence interval [CI], 66.8%–94.6%];
26/30 protected) than the standard monthly full-dose regimen (62.5% [95% CI,
29.4%–80.1%]; 10/16 protected) against infection 3 weeks after the third dose [31].
. Additional applications for RTS,S
Additional applications of RTS,S explored through modelling and, if indicated, evaluated
in carefully designed field studies over the next 5-year period include the following [33]:
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In the elimination context, a malaria diagnostic tool is needed for reactive or proactive
detection of infectious parasite reservoirs residing in those individuals with subclinical infec-
tions and/or with parasite densities lower than those reliably detected with existing RDTs and
microscopy (Fig 1) [73]. A target product profile (TPP) has been developed for a point-of-care
malaria infection detection test for rapid detection of low-density, subclinical malaria infec-
tions [64]. Provided this was sufficiently sensitive, it would potentially enable targeting of pop-
ulations harbouring reservoirs of parasite biomass with interventions interrupting
transmission.
The most efficient uses for digital health are still being explored in malaria, but integrating
diagnostic results generated from malaria case management into elimination programme sur-
veillance efforts offer a near-term opportunity to fill critical data gaps in mapping malaria
prevalence [2,7]. For example, 1 study combined a globally accessible database with mobile
phone-based imaging of RDTs to provide an objective diagnostic readout and automated col-
lection of surveillance data [74]. A similar approach in Kenya used digital RDT readers with
upload to a cloud database [75]. However, lessons learned from digital health applied to the
eradication programme for tuberculosis suggest that attaining a population-level impact are
undermined by insufficient scale, coordination, and end-user engagement [76]. These issues
are likely compounded in malaria given the higher prevalence of the disease globally.
Approaches to developing diagnostics. Several biomedical engineering approaches for
malaria parasite detection have been investigated [77], including automated image processing
[78], microfluidic systems [79], microarray chips [80], dielectrophoresis [81], and exploiting
the bioelectrical properties of blood [77]. Further development of these techniques to increase
sensitivity and specificity to detect clinically unapparent malaria parasite infections and allow
field deployment continues.
Simplified molecular methods to detect low-level P. falciparum parasitaemia for use in low-
resource settings are being developed, although improvements in throughput and cost are
required [82]. Loop-mediated isothermal amplification (LAMP) is 1 promising approach,
already validated in low-transmission settings [83] and as point-of-care detection of asymp-
tomatic low-density malaria parasite carriers [84]. Further developments include noninstru-
mented nucleic acid amplification LAMP (NINA-LAMP) [85], achieving comparable
sensitivity to P. falciparum polymerase chain reaction (PCR) detection in the field [85,86].
Another approach, using an insulated isothermal PCR (iiPCR) in a commercially available
portable device, for Plasmodium detection achieved an assay efficiency of 96.9% with a lower
detection limit of100 copies of plasmodial DNA [87]. Nucleic acid amplification techniques
• Evaluating the contribution to elimination of artemisinin-resistant parasites in the
Greater Mekong Subregion, although data supporting an adult indication (dose and
regimen) would be needed [32];
• Combining RTS,S with other interventions or another malaria vaccine (mass drug
administration [MDA] or a future VIMT, respectively), with the aim of enhancing
or extending their effects;
• Combining RTS,S with seasonal malaria chemoprevention (SMC), a study of which
is in progress in Burkina Faso and Mali.
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can also be used for multiple pathogens in parallel, incorporating other infectious diseases
(e.g., Ebola, dengue, and typhoid), depending on the setting and target population [88].
Box 2. Tools for developing tools: Demonstrating transmission-
blocking activity
The validation of surrogate end points for transmission-blocking activity that translate
into known effects in the field is necessary for the efficient development of new interven-
tions aimed at this target.
Mosquito feeding assays
Three assays are available for assessing transmission-blocking activity:
• Direct feeding assay (DFA): allowing mosquitos to feed on parasitaemic hosts; the
most ‘physiologically relevant’ method [46,47].
• Direct membrane feeding assay (DMFA): blood samples from parasitaemic hosts are
fed to susceptible mosquitoes through an artificial membrane [48].
• Standard membrane feeding assay (SMFA): laboratory-reared mosquitoes are fed a
controlled number of cultured gametocytes from a single parasite strain combined
with uninfected human erythrocytes and serum from human volunteers or animals.
SFMA is now available as a medium throughput, reproducible, standardised assay
[49].
In the context of elimination, the relevant outcome from these assays is a reduction in
the number of infected mosquitoes.
Controlled human malaria infection (CHMI) model
Three CHMI techniques have been developed to determine the ability of drugs and vac-
cines to prevent human infection:
• Sporozoite mosquito bites: infection of human volunteers via mosquito biting [50,51].
• Sporozoite direct venous inoculation (SDVI): injection of sporozoites into human vol-
unteers [52,53].
• Induced blood-stage malaria parasite infection (IBSM): administration of Plasmo-
dium-infected red blood cells to human volunteers [54,55].
Each of these techniques has advantages and disadvantages. Both sporozoite-based mod-
els allow evaluation of preerythrocytic and blood-stage drugs and vaccines, whereas
IBSM can determine blood-stage efficacy only.
To evaluate transmission-blocking efficacy in preventing transmission from humans to
mosquitoes, CHMI can be followed by a mosquito feeding assay using blood or serum
from CHMI volunteers. Development of a regulatory pathway using mosquito feeding
assays and CHMI with relevance to transmission-blocking activity in the field is ongo-
ing. This effort would benefit from the development of new vaccines and drugs aimed
specifically at this indication [56].
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Fig 1. Tools for detecting and interrupting malaria transmission and their action in the malaria transmission cycle.
https://doi.org/10.1371/journal.pmed.1002455.g001
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Noninvasive testing
Although a noninvasive technique is highly preferred, all currently available diagnostics
require blood samples. PCR-based assays to detect Plasmodium parasites in saliva, although
unsuitable for routine diagnosis, have been successfully developed [89]. Malaria detection in
urine has been evaluated in field trials, but its sensitivity requires improvement [90]. Prelimi-
nary investigations indicate that malaria-specific volatile levels from breath samples correlate
with parasite clearance [91], and studies are ongoing. A transdermal, noninvasive, reagent-free
approach relying on the presence of iron-rich haemozoin to generate vapour nanobubbles is
currently being field tested to detect parasites in skin blood vessels [92].
Detecting gametocytes
While gametocyte detection may indicate an individual’s transmission potential, further defi-
nition is required as to the most appropriate clinical sample to collect and the relevant gameto-
cyte levels reflecting infectiousness [47]; this is complicated by a lack of correlation between
gametocyte density in the blood and infectiousness following antimalarial treatment [93]. Vali-
dation of relevant target sequences is a first step towards development of molecular methods
amenable for routine gametocyte detection. Circulating P. falciparum female and male and
P. vivax gametocytes can now be detected using quantitative nucleic acid sequence-based
amplification (QT-NASBA) or quantitative PCR (qPCR) methods with pfs25-, pfs230p-, and
pvs25-based primers, respectively [94–98].
Detecting drug resistance
Detection of Kelch-propeller polymorphisms conferring artemisinin-resistance is currently
restricted to sentinel surveillance [21], though more granular information is needed with con-
tinuing efforts to eliminate artemisinin-resistant parasites [99]. For example, a next-generation
amplicon sequencing method suitable for use in endemic countries enables high-throughput
detection of genetic mutations in 6 P. falciparum genes associated with resistance to antimalar-
ial drugs, including artemisinins, chloroquine, and sulfadoxine-pyrimethamine [100]. For
detecting P. falciparum single nucleotide polymorphisms (SNPs) associated with antifolate
drug resistance, the ligase detection reaction fluorescent microsphere (LDR-FM) assay has
been validated in clinical trials in Uganda [101]. As noted elsewhere in the malERA Refresh
series [8], continued research on identifying markers of resistance to the other antimalarial
drugs in current use (e.g., lumefantrine and piperaquine) is critical, as tools are needed to
detect and manage drug resistance inevitable in elimination efforts [102,103].
Detecting hypnozoites
Hypnozoites residing in the human host is one tactic used by P. vivax and P. ovale to sustain
the parasite reservoir between transmission seasons and produce multiple clinical relapses
over prolonged periods, each with the potential to maintain transmission [104]. Detecting
P. vivax/P. ovale hypnozoites, however, is problematic because of their low density, metabolic
inactivity, and sequestration within the liver. Biomarkers that detect hypnozoites would be
breakthrough tools in both case management diagnostics and elimination surveillance for
P. vivax and P. ovale infections.
Glucose-6-phosphate dehydrogenase (G6PD) testing
An affordable, easy-to-use, rapid, point-of-care, semiquantitative diagnostic test is needed to
identify G6PD-deficient individuals at risk of haemolysis with use of 8-aminoquinolones (i.e.,
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primaquine or tafenoquine) to prevent P. vivax relapses. Although several tests are available
[105], further refinement is needed to support greater access to these medicines. Single admin-
istration of low-dose (0.25 mg/kg) primaquine as a gametocytocidal agent is recommended
after treatment for P. falciparum malaria [106], but there is still a need for more data on the
optimal dose and reassurance of safety in G6PD-deficient individuals and larger populations,
if used in MDA, for example [107].
Pregnancy testing
Pregnant women are excluded from receiving certain drugs or interventions, and rapid, low-
cost, low-complexity, point-of-use pregnancy tests are needed, particularly for populations
receiving MDA drugs with contraindications for use during pregnancy.
Challenges
Diagnostics are needed to direct treatment, support surveillance, and identify transmission
reservoirs [73] and for continued progress in the development and evaluation of other tools
for elimination, e.g., in settings with low-density parasitaemia and low transmission and for
interventions targeting hypnozoites/prevention of relapse. The relevance of low-density para-
sitaemia to transmission requires further investigation to enable the design of diagnostics
appropriate for these needs. Longer term, development of noninvasive assays, and field assays
for detecting drug-resistant parasites should be pursued. Detecting hypnozoites remains a
more profound challenge, although proteomics and metabolomics are being explored [108].
Drug research agenda
Drugs for malaria treatment, prevention, and transmission interruption
A strong portfolio of combination medicines with different or competing resistance mecha-
nisms is required to combat resistance. It is now possible to tune the development program to
advance drugs that have high barriers to resistance development and a low potential for cross
resistance with other agents. In addition to classic inhibitory experiments, the propensity of
drugs to induce ring-stage dormancy, characteristic of artemisinin resistance, must also be
evaluated [109].
Single encounter radical cure and prophylaxis (SERCaP). Proposed in malERA 2011,
SERCaP remains a priority [5]. Radical cure means clearance of all asexual blood-stage forms,
mature gametocytes, and P. vivax/P. ovale hypnozoites (Fig 1). Combination therapies of new
chemical entities (NCEs) that are targeted to ‘single encounter, radical cure‘ are now in phase
II clinical trials, with potential regulatory submission dates circa 2021 (S1 Table) [17].
The post-treatment prophylactic component of the SERCaP will come from the long half-
life of the active pharmaceutical ingredients. Malaria parasite elimination will require new gen-
erations of single-encounter chemoprotection, to protect migrating populations and protect
against epidemics in the later stages of elimination. These products would include molecules
that provide chemoprotection by targeting the preerythrocytic stages (see TCP-4 specific attri-
butes in [110]).
Reducing duration of dosing regimens, ideally to a single dose, increases adherence, be it
for prevention or treatment [8]. Although better adherence improves effectiveness, it must be
achieved without significantly increasing the risk of selection for drug-resistant parasites as a
result of creating long periods of subtherapeutic drug levels. As a country or area approaches
elimination, the remaining parasites are likely to be those most resistant to treatment, and
drug classes with a low propensity to select for parasite resistance should be prioritised [111,
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112]. The temptation to combine new drugs with old drugs with preexisting resistance, whilst
simpler from a regulatory perspective, must be avoided to prevent novel agents being exposed
as functional monotherapies when used against strains resistant to the older partner drug.
Severe malaria. Intravenous and intramuscular artesunate are currently the most effective
and well-tolerated treatments for severe malaria [113,114], with rectal artesunate recom-
mended for pre-referral treatment of children who cannot quickly access hospital care [106].
The potential spread of artemisinin resistance threatens the effectiveness of artesunate for
treatment of severe malaria. Thus, new compounds with rapid activity against asexual blood
stage parasites, suitable for parenteral administration, are needed for this critical indication
(see TCP-1 specific attributes in [110]). The decline in the incidence of severe malaria in adults
will require alternative development approaches, including the development of surrogate end
points [115], as not enough patients will be available for large mortality studies [116]. How-
ever, sufficient safety data in adults would still be required for a phase III trial in African chil-
dren with severe malaria.
Interrupting transmission. Drugs with activity against gametocytes in humans or that
impair sporogony in the mosquito could help to interrupt transmission (Fig 1) [117]. While
low-dose (0.25 mg/kg single dose) primaquine is currently recommended as a gametocytocidal
following ACT treatment for P. falciparum malaria in areas of low transmission [16,118,119],
NCE combination therapies with both therapeutic and transmission-blocking activity would
simplify drug administration. High-throughput screening and clinical evaluation of com-
pounds with transmission-blocking activity are now possible (Box 2) [59,120–125] and have
yielded new leads, including more than a dozen from the Medicines for Malaria Venture
toolbox with activity in the standard membrane feeding assay [126].
Global antimalarial drug development portfolio. There are at least 15 active projects in
preclinical development or phase I or II clinical trials (S1 Table) [17]. A range of new chemo-
types targeting new parasite pathways are available, with antimalarial drug development accel-
erated using CHMI models (Box 2). Two pairs of NCE combinations are in phase II clinical
studies: the long-lasting synthetic endoperoxide artefenomel (OZ439) combined with the
next-generation 4-aminoquinoline, ferroquine; and the imidazolopiperazine KAF156 com-
bined with a new once-per-day lumefantrine formulation. This latter combination is also
being explored as a 3-day regimen for use as a frontline agent in areas with ACT resistance.
Single-dose effectiveness with an appropriate safety profile may require triple combination
therapy. Notably, KAF156, DSM265, and MMV390048 have activity against P. falciparum liver
stages and could be given as a single-dose treatment or once weekly for chemoprotection (S1
Table) [127]. TPPs and target candidate profiles with minimal essential and ideal attributes for
single-encounter chemoprotection have been published [110].
Antihypnozoite drugs
In areas of high transmission, such as Papua New Guinea, relapses cause approximately 4 of
every 5 P. vivax infections [128]. Modelling suggests that for rapidly relapsing tropical P. vivax
strains, effective relapse prevention has the potential to significantly reduce transmission [104].
In areas of seasonal transmission, relapses allow parasites to rapidly reestablish transmission
once vector populations recover [129]. The 8-aminoquinoline primaquine is the only antirelapse
therapy currently available (aside from chloroquine, to which there is extensive resistance), but
treatment courses are 7–14 days, and poor adherence undermines effectiveness [130]. Tafeno-
quine is a candidate single-dose 8-aminoquinoline, showing high antirelapse efficacy in P. vivax
infections when given with chloroquine [18]. Phase III clinical trials were completed in 2016,
with regulatory submission anticipated in 2017. The impact of tafenoquine on transmission
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remains to be evaluated in post-registration CHMI and field trials. G6PD-deficient individuals
cannot be given standard doses of 8-aminoquinolones; in addition, 8-aminoquinolones are con-
sidered contraindicated during pregnancy and lactation. As such, new antihypnozoite drug clas-
ses without these contraindications are needed. Discovery should be enhanced in the next 5
years through screening campaigns against P. vivax liver stages using stable human cell systems
[131,132]. Additionally, humanised mouse models are facilitating drug development against this
life cycle stage that thus far has been refractory to study [133].
Seasonal malaria chemoprevention (SMC)
In areas where malaria is seasonal, providing SMC by monthly treatment with long-lasting
antimalarial drugs greatly reduces malaria burden in children under 5 years of age [134,135].
Modelling studies indicate the potential for reducing transmission to very low levels if SMC is
combined with long-lasting insecticidal nets (LLINs) at 80% coverage and expanded to chil-
dren up to 10 years of age [136]. Sulfadoxine-pyrimethamine + amodiaquine (SPAQ) is used
for SMC in the Sahel; drug resistance prevents SPAQ use in eastern and southern Africa,
and there are concerns that resistance may spread to the Sahel. Thus, alternative drugs are
required, ideally with simplified dosing regimens.
Endectocides
Endectocides are an alternative approach to malaria control whereby humans and/or livestock
are given agents with insecticidal activity, resulting in reduced survival of the vector upon
blood feeding and impairment of malaria parasite transmission [137]. Modelling studies sug-
gest that the endectocide ivermectin could help achieve transmission interruption as an addi-
tional intervention in settings where mass treatment strategies with ACTs alone would be
insufficient to accomplish elimination [138]. A research agenda was proposed in 2013 outlin-
ing the path for ivermectin use in malaria [139], with a number of studies in different settings
underway. A WHO expert group recently examined this concept, with findings anticipated in
2017. The antimosquito properties of veterinary and other candidate endectocides are also
being explored.
Novel formulations
An interesting possibility is the application of nanomilling and related technologies to develop
long-acting drug formulations, which are being investigated for long-term HIV preexposure
prophylaxis and in combination with contraception in so-called multipurpose prevention
technologies (MPTs) [140–143]. Such long-acting drug formulations could potentially allow
chemoprotection over several months from a single injection. Application to new generations
of transmission-blocking molecules or endectocides could provide tools that reduce or prevent
transmission over an entire transmission season.
Challenges
Attrition rates in antimalarial drug development are comparable with those in other infectious
diseases [126]. Thus, discovery momentum needs to be maintained at high levels if new drugs
are to reach licensure. A major challenge in registering NCEs for malaria is assembling the
substantial clinical safety data required for regulatory approval, particularly in the key target
populations of infants and pregnant women. Thus, reproductive safety should be evaluated
early in preclinical development to prioritise investment in NCEs with appropriate preclinical
profiles.
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With the introduction of NCEs during the next 5 years, pharmacovigilance needs strength-
ening in malaria-endemic areas. This is also a prerequisite for safe deployment of current
ACTs and next-generation treatments during mass treatment programmes targeted at popula-
tions that include individuals with subclinical malaria or who are infection free.
In the next 5–10 years, there is a need to enrich the early-stage portfolio with new antihyp-
nozoite drugs beyond the current 8-aminoquinolones. Cell biology and the animal models
supporting drug discovery for new antihypnozoite agents have progressed significantly but are
still not amenable to high-throughput screening programmes [144,145]. Clinical trials for
relapse prevention take 6–12 months, much longer than treatment trials. Additionally, relapses
can be caused by hypnozoites that are homologous or heterologous to the initial infection and
cannot, therefore, be distinguished from recrudescence or reinfection [146–148], except by the
physical removal of treated patients from transmission areas, e.g., repatriated soldiers and
travellers.
Although NCEs active against artemisinin-resistant isolates are in development, better
strategies are needed to deploy drugs to delay or prevent the emergence of drug resistance,
such as measures to tackle counterfeiting or manufacturing of poor-quality medicines, drug
sequencing, multiple firstline therapies, and exploiting competing resistance mechanisms, as
discussed elsewhere in the malERA Refresh series [8].
Vaccine research agenda
The Malaria Vaccines Technology Roadmap was updated in 2013 [34], with the goal of devel-
oping by 2030 vaccines for P. falciparum and P. vivax that have a protective efficacy of at least
75% against clinical malaria and/or reduce transmission of the parasite. The roadmap outlines
key priorities in research, vaccine development, key capacities, policy, and commercialisation.
The research issues in malaria vaccines are discussed below, but key to their success will be
ensuring an efficient and cost-effective distribution system and redirection of the health sys-
tem from delivering malaria treatment to prevention and transmission interruption [9].
Vaccines to prevent clinical malaria and interrupt transmission
A preerythrocytic vaccine to interrupt malaria transmission (PE-VIMT) that completely pre-
vents liver-stage infection for a significant duration (e.g., at least 1 transmission season) would
prevent parasitaemia and gametocyte generation and therefore interrupt onward transmission
(Fig 1). Although RTS,S is a preerythrocytic vaccine, demonstrating modest efficacy in pre-
venting clinical malaria, prevention of infection and transmission were not evaluated in the
late-stage clinical trials (Box 1). More recently, a delayed fractional dose regimen of RTS,S
with improved efficacy against a parasite transmission (mosquito-to-human) end point may
be considered for transmission-blocking potential (Box 1) [31]. Several next-generation preer-
ythrocytic candidates are in clinical development, including multistage (including asexual
blood-stage and/or sexual/sporogonic/mosquito-stage targets) combinations and prime-boost
strategies, as well as irradiated or genetically attenuated sporozoites (S2 Table) [35,149]. Future
directions need to ensure a widely acceptable route of administration, optimised dose regi-
mens, and lower inoculum sizes.
Blood-stage vaccines are an alternative and complementary approach to PE-VIMT. Blood-
stage vaccines that interrupt malaria parasite transmission (BS-VIMTs) by efficiently clearing
blood-stage infections would limit gametocyte densities and the duration that a person is infec-
tious, thus reducing human-to-mosquito malaria parasite transmission (Fig 1). Several prom-
ising P. falciparum vaccine candidates are in clinical development [150], including the
unstructured peptide P27A, the well-studied PfRH5, and the 2 placental malaria vaccine
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candidates PAMVAC and PRIMVAC (S2 Table). Innovative new concepts in next-generation
malaria vaccine protein subunit design are being explored to develop highly effective multi-
component/multistage/multiantigen formulations [151].
Vaccines that only interrupt malaria parasite transmission
Sexual-sporogonic-mosquito-stage vaccines to interrupt transmission (SSM-VIMT) inhibit
parasite transmission from human to mosquito, through reducing gametocytes’ ability to
infect mosquitoes or by interfering with parasite development (sporogony) within the mos-
quito (Fig 1). As the potential benefit to the recipient is both delayed and indirect, the PATH
Malaria Vaccine Initiative and partners are exploring potential regulatory and policy
approaches with the United States Food and Drug Administration and WHO, respectively
[152,153]. Progress has been made, with a design proposed for a phase III study [154]. The
Pfs25 antigen is expressed on the surface of zygotes and ookinetes in the mosquito midgut,
and various attempts to improve immunogenicity and transmission-blocking activity have
been undertaken (S2 Table) [36,153]. The most clinically advanced is Pfs25-EPA (a detoxified
form of exotoxin A from Pseudomonas aeruginosa) conjugate [155]. Most recently, Pfs25 has
been fused with IMX313, a molecular adjuvant, and expressed in chimpanzee adenovirus 63
(ChAd63) and Modified Vaccinia Virus Ankara (MVA) viral vectors and as a secreted protein
nanoparticle [156]. The research agenda has broadened to include other SSM-VIMT antigens,
including Pfs230 and Pfs48/45 (S2 Table).
Vaccines for P. vivax/P. ovale
A vaccine that could prevent P. vivax/P. ovale infection and hypnozoite formation, target hyp-
nozoites, or prevent disease, thereby interrupting transmission and draining the hypnozoite
reservoir, would be a significant step for accelerating malaria elimination (Fig 1). P. vivax is
now included in the Malaria Vaccine Technology Roadmap strategic goals [34]. While basic
research in P. vivax has increased in recent years, no vaccine candidate has progressed past
early human studies (S3 Table) [35,36]. Three preerythrocytic vaccines have reached clinical
trials [157–159]. A blood-stage vaccine targeting the Duffy-binding protein region II has pro-
gressed to early clinical trials [160], though combination with other blood-stage antigens is
likely necessary to achieve high growth inhibition. The Pvs25 antigen is also being investigated
as an SSM-VIMT. The recent development of P. vivax CHMI systems allows evaluation of vac-
cine efficacy [157,161]. Also, publication of the P. ovale and P. malariae genomes facilitates
antigen discovery for these parasites [162].
Adjuvants, delivery platforms, and desired human immune responses
Most (but not all) malaria vaccines in development are based on Plasmodium protein subunits
and have shown limited immunogenicity in humans. Suitable adjuvants and delivery platforms
are therefore needed to elicit the desired immune response and induce significant protection
from infection and disease without unacceptable collateral inflammation [163]. There are few
adjuvants licensed for human use and there is a need to (1) better define the desired human
immune response; (2) facilitate access to adjuvants in development and ensure downstream
availability, affordability, and acceptability; (3) develop more specific targeted adjuvants that
boost desired immune responses while maintaining acceptable safety; and (4) match individual
adjuvants to individual vaccine candidates depending on the postulated mechanism of action
while maintaining compatibility for combination vaccines.
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Prophylactic biologics
Monoclonal antibodies are another potential tool. Recently, the major barriers of cost are
being overcome through improvements in manufacturing and high-expressing cell lines [164].
A recent report estimated that the cost of goods for monoclonal antibodies had reduced
10-fold, from thousands of dollars per gram to around $100 per gram, with the costs of devel-
oping these agents comparable to other therapeutic drugs and vaccines [165]. Additionally, the
volume and frequency of administration of monoclonal antibodies have been reduced by
improvements in potency and pharmacokinetics [166]. There has been a significant increase
in the number of validated vaccine targets, and now monoclonal antibodies can be studied
early in clinical development for their ability to provide immediate protection in CHMI mod-
els, either singly or in combination [167]. Antibodies are less prone to the off-target safety and
toxicity issues that often plague small molecule development and thus offer significant advan-
tages for deployment in vulnerable populations, including the immunocompromised and
pregnant women. In the context of elimination, monoclonal antibodies with suitable pharma-
cokinetics/pharmacodynamics could represent an alternative to active immunisation by
VIMTs or transmission-blocking drugs. As with any tool, prophylactic biologicals will need to
be designed to meet the needs and capabilities in target settings.
Challenges
To achieve malaria elimination, vaccines would ideally be able to prevent infection by all 5 spe-
cies of human malaria parasites. While humans are the major (if not only) reservoir for 4 of 5
Plasmodium ssp., zoonotic P. knowlesi presents a unique challenge for elimination given con-
tinuous sylvatic transmission [168]. If a ‘Plasmodium’ vaccine targeting all human-infecting
species is not feasible, then vaccines are required against individual species. It remains to be
determined whether experience gained in the development of P. falciparum vaccines can, in
fact, inform approaches to other malaria species or whether new strategies are required.
Similar to drugs used in MDA, vaccines for mass inoculation need to be safe for use in preg-
nant women and children. Demonstrating safety across the target population is particularly
important for vaccines that only prevent transmission and have an indirect benefit to the
recipient.
For malaria vaccine candidates, there is limited information on immune correlates that
may predict efficacy in the chosen indication. Antigenic diversity of many of the malaria vac-
cine targets [169,170] adds additional complexity to predicting efficacy and enables parasites
to evade host immune responses, potentially leading to vaccine escape mutants [171,172].
There is also incomplete understanding of the development and maintenance of either nat-
urally acquired or vaccine-induced human immunity to Plasmodium. A predictable ‘age shift’
in peak incidence of malaria associated with vaccines with modest and/or waning efficacy in
children who have not acquired full natural immunity must be anticipated and appropriately
managed [173]. The challenge of maintaining individual and population-based (herd) immu-
nity may increase as circulating parasite prevalence declines during the later stages of elimina-
tion. Thus, rationally designing vaccines that induce long-lasting immunity in semi-immune
adults and provide broad cross strain protection presents formidable challenges.
Finally, as with drugs, parasite genetic diversity and rich population structures, particularly
in high-transmission settings, indicate the potential for differential parasite-specific efficacy
and selection of resistant Plasmodium. The former has been observed in vaccine field studies,
including a recent genetic analysis associated with a large phase III trial of RTS,S/AS01 [170].
However, there are no data regarding whether implementing malaria vaccination induces par-
asite resistance in the whole population of infected individuals.
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Vector control research agenda
Insecticide-based interventions
LLINs are currently the single most important malaria control intervention, responsible for
approximately 68% of malaria cases averted in Africa [174]. However, emerging resistance to
insecticides among Anopheles mosquitoes threatens to reverse these gains [175,176]. New
insecticides with different modes of action are urgently needed to deter resistance develop-
ment. In response, ‘Innovation to Impact’ was initiated in 2013 with an aim to transform the
process for developing and delivering life-saving vector control products for diseases caused
by vector-borne pathogens. More than 30 different stakeholder groups are involved, including
industry, global evaluation and regulatory bodies, procurers, local and national representa-
tives, and donors [42,43].
Twelve insecticide products are currently available for vector control, confined to 4 chemi-
cal classes (pyrethroids, organochlorines, organophosphates, and carbamates), although only
pyrethroids are widely used for LLINs. Several combination LLINs consisting of different
insecticide classes or incorporating the synergist piperonyl butoxide are in late-stage develop-
ment (Table 1) [39–41,177–181]. Similar to LLINs, long-lasting insecticide-treated hammocks
could be effective in remote areas; however, the lifespan of these interventions has a significant
impact on cost-effectiveness, and exploration of technologies to increase durability is needed
[182].
After screening around 4 million compounds, 3 new insecticides have progressed to devel-
opment, with registration typically taking 5–7 years [44,178]. These new insecticides are pri-
marily pyrethroid alternatives for use in LLINs but also would be expected to have use in IRS.
For IRS, 2 long-lasting formulations of existing compounds have become available: a microen-
capsulated formulation of the organophosphate insecticide pirimiphos methyl in 2012 [37]
and a polymer-enhanced suspension of deltamethrin in 2013 [38]. The Next Generation IRS
project is a market intervention to accelerate uptake and increase use of long-lasting IRS prod-
ucts [183]. Additional long-lasting insecticides suitable for IRS are in development (Table 1).
Table 1. Insecticides for indoor residual spraying (IRS) under World Health Organization Pesticide Evaluation Scheme (WHOPES) evaluation and
long-lasting insecticidal nets (LLINs) in late-stage development [39–41,177,178]*.
Application Product Insecticide(s)
IRS Phantom Chlorfenapyr (phase III)
SumiShield Clothianidin (phase II)
Fludora Fusion Deltamethrin + clothianidin (phase II)
LLINs DawaPlus 2.0 Deltamethrin coated on polyester
LifeNet Deltamethrin incorporated into polypropylene
MiraNet Alpha-cypermethrin incorporated into polyethylene
Panda Net 2.0 Deltamethrin incorporated into polyethylene
Yahe Deltamethrin coated on polyester
LLINs + PBO Olyset Plus Permethrin + PBO incorporated into polyethylene
PermaNet 3.0 Deltamethrin coated on polyester side panels; deltamethrin + PBO incorporated into polyethylene (roof)
Veeralin Alpha-cypermethrin and PBO incorporated into polyethylene
Combination LLINs Olyset Duo Pyriproxyfen and permethrin incorporated into polyethylene
Interceptor G2 Alpha-cypermethrin + chlorfenapyr coated on polyester
*March/April 2016.
PBO, piperonyl butoxide
https://doi.org/10.1371/journal.pmed.1002455.t001
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New ways of using insecticides require more extensive field evaluation, e.g., technological
advances for improving spraying techniques [184], timing of insecticide deployment to coin-
cide with seasonal transmission, slow-release polymer-based wall linings [185,186], insecti-
cide-treated eave tubes or eave ‘bricks’ combined with house screening, and electrostatic
coatings to enhance insecticide bioavailability [187].
Vector behaviour and outdoor targeting
Greater understanding of vector behaviour is needed, including the behavioural adaptations of
vectors in response to control measures, such as changes in biting times, resting locations, and
rates of zoophagy [188–194]. Improved targeting of specific vector behaviours—particularly
sugar feeding, oviposition, mating, dry-season survival, and swarming behaviour—and zoo-
prophylaxis are generating novel approaches to vector control, with potential application
across transmission settings [195,196].
Long-standing evidence that malaria parasite transmission to humans occurs outdoors in
Southeast Asia and South America and increasing evidence of outdoor transmission in sub-
Saharan Africa [3,197–202] suggest a specific need for interventions that target mosquitoes
outside dwellings. Attractants/traps are a potential new area of mosquito control that can be
applied both indoors and outdoors. These include attractive toxic sugar baits [203,204] and
sound traps, which lure male mosquitoes by broadcasting sounds similar to the wingbeats of
female mosquitoes [195,203]. All major malaria parasite vectors in Africa mate in swarms
[206], which are easily found and recognised, appear to be stable over time, and exist in a
defined space [195]. This facilitates close targeting either with insecticides or traps [195]. Spa-
tial repellents are another approach, releasing into the air volatile chemicals that prevent
human–vector contact within the treated space (indoor or outdoor). Guidelines for efficacy
testing are now available [205,207], and evaluation in outdoor settings is needed [208,209].
Environmental management and larval source management
Environmental management, such as improved housing and water management, can be highly
effective in specific epidemiological and environmental settings [210]. The best of these envi-
ronmental management approaches require further investigation in tropical climates and
resource-poor settings to establish their epidemiological impact in these settings [210,211].
Mosquito larval source management is the management of water bodies that are potential lar-
val habitats to prevent immature mosquitoes developing into adults, either by environmental
management or application of larvicides [45]. Larval source management has been highly
effective in certain situations [211], but as this is a resource-intensive activity, better definition
of the appropriate requirements and approaches across a wider range of settings is needed.
Genetic approaches
There are 2 main strategies for genetically modifying mosquito populations: (1) population
suppression, whereby mosquitoes are modified in such a way that upon mating with the wild
type the resulting progeny are either sterile or dysfunctional, and (2) population alteration or
replacement, in which the mosquitoes are modified in such a way that upon mating with the
wild type, the resulting progeny are rendered refractory to malaria parasite infection. Genetic
approaches now appear operationally feasible given recent advances in molecular biology,
such as the efficient genome-editing techniques based on CRISPR/Cas9 and other approaches
[10,212,213].
The sterile insect technique was the first attempt at genetic population suppression,
whereby large numbers of irradiated sterile males are released with the hope that females mate
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unsuccessfully [214]. A more recent development is the release of insects carrying a dominant
lethality, with the progeny of females mating with genetically modified males inheriting a
lethal gene [215,216].
Gene drive systems exploit ‘homing’ endonucleases. These induce the lateral transfer of an
intervening DNA sequence to a homologous allele that lacks that sequence, thereby changing a
heterozygote into a homozygote. Conventional homing endonucleases have been reengineered
to recognise mosquito genes [217] and can rapidly increase the frequency of desirable traits in
a mosquito population [218]. Technical feasibility has been demonstrated for a CRISPR/Cas9--
based gene drive system with the potential to reduce mosquito populations [219] or make
them less able to transmit malaria parasites [220].
There is also the potential for symbiont-mediated biocontrol in malaria Anopheles mos-
quito populations, as suggested by recent successes achieved against Aedes aegypti (e.g., Wolba-
chia-mediated pathogen interference for dengue control). A further step is paratransgenesis,
whereby a vector symbiont (virus, bacteria, or fungi) is engineered to express ‘effector’ mole-
cules within the vector that are deleterious to the pathogen. Genetic modification of symbionts
is easier than it is for mosquitoes and is independent of mosquito species, providing the symbi-
ont can survive and colonise the host [221], and laboratory studies have shown promise [222].
There are environmental uncertainties associated with widespread distribution of technolo-
gies involving genetic manipulation of pathogens, vectors, or their symbionts [10,212]. Phased
testing starting at a small scale is recommended, though the parameters for ecological risk
assessment are not well understood.
Challenges
The development of new insecticides will need to outpace the expansion of insecticide-resis-
tant alleles in mosquito populations, and new products will need to be deployed to effectively
combat behavioural resistance [8]. The imperfect correlation between entomological indica-
tors and disease incidence complicates the accurate assessment of new vector control tools.
Randomised controlled trials are expensive and time consuming, and new pathways should be
explored for generating evidence for large-scale implementation of new interventions. Increas-
ing fine-scale heterogeneity, in human and vector subpopulations and in geographic space,
means that no single set of interventions will be effective across large areas or districts. Not-
withstanding resource availability, the challenge is to understand which combinations of vec-
tor control measures are appropriate in different settings and how their effects can be
augmented with other interventions (e.g., endectocides, transmission-blocking drugs, and vac-
cines) [7]. Targeting mosquito dormancy remains a challenge in large part because of the pau-
city of mechanistic evidence by which vectors persist during the dry-season (e.g., diapause
[aestivation] and long-distance migration) [223]. Finally, it is important to note that there are
very few trained entomologists in national malaria control programs, especially at the district
level. To develop and implement vector-targeted interventions, greater entomology capacity
building is required.
Conclusions
There are overarching areas in which greater knowledge is required to understand the utility
of current interventions and define which products and strategies might be required going for-
ward. Novel tools may allow further investigation of knowledge gaps, and some may be bridge-
able (Table 2). The R&D agenda for tools for elimination is summarised in Box 3.
Transmission can remain high even with high coverage of good-quality case management
and vector control. Thus, products and strategies directed specifically at accelerating
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002455 November 30, 2017 17 / 35
elimination by targeting transmission are needed. Interventions may only achieve transmis-
sion reduction when deployed in certain populations or settings. Conversely, some popula-
tions and settings may require specific measures for transmission reduction, for example,
pregnant women and infants, migrant workers, subclinical parasitaemia, or addressing out-
door transmission. The availability of new interventions is expanding, but developing algo-
rithms for their rational combination and deployment in packages to decrease transmission is
a key research need that requires modelling support [7]. Cost-effectiveness is an important
determinant of whether particular interventions are adopted in public health programmes [9].
New products and strategies are needed to overcome parasite drug resistance and vector
resistance to insecticides [8]. Prevalence of vaccine escape mutants has been highlighted as a
potential issue if vaccines become widely used [170–172]. Thus, product development must
continue, and strategies for phased replacement are needed as effectiveness wanes. New prod-
uct discovery and development requires investment in basic science [10], the alignment of
regulatory structures to expedite product registration, and continued investment in pharma-
covigilance and surveillance. Funding organisations and malaria programmes also need to be
Table 2. Knowledge gaps and tools to potentially bridge the gaps.
Knowledge gaps Tools to potentially bridge the gaps
High-to-low transmission
• Why do transmission rates remain high even
when case management and vector control have
high coverage?
• Methods that are protective against infection and
interrupt transmission (Fig 1).
• At which point should interventions specifically
directed at reducing transmission be introduced?
• Robust mathematical and laboratory models of
transmission and impact of combination interventions.
• What is the contribution of the subclinical
reservoir to transmission in high-transmission
settings?
• Sensitive point-of-care tests to detect transmission
reservoirs and enable evaluation of interventions.
• In vector control, which factors drive changes in
transmitting species?
• Prevention or control measures effective against all
species.
Low-to-zero transmission
• How best can the remaining sources of
transmission be identified?
• Affordable, rapid, sensitive screening techniques to
identify populations generating infectious
gametocytes.
• What is the impact of nonhuman malaria parasite
transmission on the effectiveness of vector
control?
• Vector control measures with efficacy independent of
nonhuman transmission.
• How can transmission be measured when it is low
or zero?
• See Malaria Eradication Research Agenda
(malERA) Refresh ‘Characterising the reservoir and
measuring transmission’ [73].
• How can approaches to false-positive diagnostic
tests be addressed?
• Development of highly sensitive and specific tests,
along with combination testing algorithm/protocols to
identify false positives.
• How can the P. vivax/P. ovale hypnozoite
reservoir be identified and targeted?
• Development of hypnozoite diagnostics, and/or
antihypnozoite drugs/vaccines that are safe enough
for use in population-based administration.
• How can heterogeneity in transmission be
managed?
• Interventions that are safe and cost-effective enough
to be used across wider populations.
Maintaining zero transmission
• How can the efficacy of tools be measured when
transmission is zero?
• Development of validated surrogate end points of
efficacy.
• What are the drivers of epidemic malaria? • Modification of vector populations to decrease
epidemic potential; tools for epidemic response,
including for nonimmune populations.
https://doi.org/10.1371/journal.pmed.1002455.t002
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Box 3. Research and development agenda for tools for elimination
Diagnostics
Detecting transmission potential
• Malaria diagnostic tools best suited for detection of low-density, subclinical infections
• Assay for detecting infectious gametocytes
• P. vivax/P. ovale hypnozoite detection methods
• Noninvasive diagnostic tests
Directing treatment
• Stable, valid, specific, and sensitive rapid diagnostic tests (RDTs) that do not depend
on histidine-rich protein 2 (HRP2)
• Detection of drug-resistant parasites
• RDTs that detect and differentiate all relevant human Plasmodium ssp. pathogens
• Multiplexed point-of-care tests for acute febrile illness
Special populations
• Affordable, simple, and accurate point-of-care tests for glucose-6-phosphate dehydro-
genase (G6PD)-deficient individuals and pregnant women
Drugs
Drugs for prevention and treatment
• Drugs that overcome resistance to existing drugs, particularly artemisinin resistance
• A suite of combination drugs with different or competing resistance profiles
• New drugs for prophylaxis
• Simplifying therapy, with the potential objective of a single encounter radical cure and
prophylaxis (SERCaP)
• New regimens for use in seasonal malaria chemoprevention (SMC) outside the Sahel
and to potentially replace sulfadoxine-pyrimethamine + amodiaquine (SPAQ)
Drugs to interrupt transmission
• Investigation of the impact of low-dose primaquine in different settings
• New drugs with transmission-blocking potential
• Drug combinations incorporating both asexual and transmission-blocking activity
• Evaluate the impact of transmission-blocking drugs on pathogen resistance develop-
ment and investigate optimal deployment strategies
• Endectocides for use in humans and animals
Antihypnozoite drugs
• Evaluation of P. vivax transmission reduction potential with tafenoquine via relapse
prevention (draining of hypnozoite reservoir)
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Special populations
• New small molecules or antibodies with a potential indication for use during
pregnancy
Vaccines
RTS,S
• Further evaluation of RTS,S to determine the potential for increased efficacy with
alternative dosing regimens
• Assessment of RTS,S in combination with other interventions (e.g., SMC) and in other
epidemiological settings and populations
New vaccines
• Defining the required attributes of preerythrocytic or blood-stage vaccines to achieve
transmission-blocking activity
• New preerythrocytic and or blood-stage vaccines, ideally with transmission-blocking
potential
• A first sexual-sporogonic-mosquito-stage vaccine to interrupt transmission
(SSM-VIMT)
Vaccines against P. vivax/P. ovale
• Vaccines that prevent infection and hypnozoite formation, target hypnozoites, or can
interrupt transmission to eventually eliminate the hypnozoite reservoir
Adjuvants
• Access to a broader choice of adjuvants with improved risk–benefit profiles
Prophylactic biologics
• Development of monoclonal antibodies (mAbs) and combinations of recombinant
multi-mAbs products
Vector control
Insecticides and long-lasting insecticidal nets (LLINs)
• New insecticides and combinations of insecticides to overcome vector resistance
• Nonpyrethroid insecticides for LLINs
• Investigation of new insecticide deployment strategies
• LLINs with improved durability
Environmental management
• Formal investigation of larval source management in a greater variety of settings
• Development of long-lasting safe larvicides
• Development of cost-effective and socially acceptable environmental management
interventions
Genetic approaches
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convinced that tools are impactful and cost-effective [9]. However, measuring the efficacy of
tools that potentially impact transmission is problematic, particularly at the extremes of trans-
mission [154]. Thus, new diagnostics and screening methods are required to assess tool effi-
cacy in low-transmission settings and determine their contribution to maintaining zero
transmission [73]. Moreover, the development of new diagnostics with improved sensitivity,
or for specific tasks such as resistance surveillance, may fundamentally change our perception
of malaria parasite transmission and our understanding of the most appropriate interventions
required to interrupt transmission.
Finally, developing new tools can be expensive. When the malaria burden is significant, the
economic case for innovation is clear. However, as the malaria burden decreases, the economic
argument for continued development becomes more nuanced. Public–private partnerships,
which first emerged 15 years ago, have demonstrated the ability to partner and drive develop-
ment for a variety of tools, including diagnostics (e.g., PATH and Foundation for Innovative
New Diagnostics), drugs (e.g., Medicine for Malaria Venture and formerly Drugs for
Neglected Diseases Initiative), vaccines (e.g., PATH Malaria Vaccine Initiative and European
Vaccine initiative), and vectors (e.g., Innovative Vector Control Consortium and more broadly
Malaria No More). New business models to attract and engage industry in developing tools for
• Development of scalable genetic approaches
• Development of environmentally and socially responsible methods for field testing
transgenic organisms
Exploiting vector behaviour
• Novel interventions to target populations and behaviours
• Increased entomological support for key decisions by national malaria programmes
Combination and mapping
• Modelling to suggest the most effective and efficient combinations of vector control
for different settings
• Developing operationally relevant mapping tools to identify and target residual
transmission
‘Tools to develop tools’
• Validating outcomes from animal and human infection models that predict a reduc-
tion in transmission in real-life settings
• Robust mathematical and laboratory models of transmission and impact of combina-
tion interventions
• Increased understanding of parasite–host immunity and mechanisms of acquired and
vaccine-induced protective and transmission-blocking immunity
• Development of high-throughput screening assays and evaluation assays for the identi-
fication and selection of compounds with neglected profiles (e.g., antihypnozoite
activity)
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the elimination should be considered as well. Interventions will be directed at increasingly
smaller populations, but these populations often represent the most difficult contexts in which
to achieve elimination, and multiple interventions may be required. Once a country achieves
elimination, there is the temptation to scale back infrastructure and interventions for malaria.
This risks triggering a potentially lethal outbreak that could be difficult to reeliminate or even
contain. There are numerous examples from earlier malaria elimination campaigns in the
1950s and 1960s of initial successes that were followed by resurgence as campaigns were
deprioritized or discontinued administratively, financially, and technically. Unless malaria can
be completely eradicated, interventions to maintain malaria elimination and a reserve of effec-
tive measures to counter malaria outbreaks will always be needed. However, if the right prod-
ucts and strategies are developed, and if they are used efficiently, effectively, and consistently,
malaria eradication is an achievable goal.
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